London Stock Exchange welcomes Ergomed plc Limited to open trading
London Stock Exchange formally welcomed Ergomed plc Limited to its markets today. Founded in 1997, Ergomed plc is a profitable UK-based company, dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs.
Ergomed plc joins AIM after a successful placing raising £11 million from new investors. Shares in the Company begin trading at 08:00 today, 15th July 2014 under the ticker symbol “ERGO”, and the ISIN number GB00BN7ZCY67.
To celebrate the occasion, Dr. Miroslav Reljanovic, Chief Executive Officer of Ergomed plc, joined Marcus Stuttard of London Stock Exchange, to open trading in London this morning.
Commenting on today’s announcement, Dr. Reljanovic said: “The fundraising and Admission to AIM are very important landmarks for Ergomed. We believe that the support shown by our new investors is testament to their understanding of the growth potential of our core services business and the value to be created from our co-development business.
“As an international, profitable and fast growing company with a fifteen year track record of providing global drug development services, Ergomed is well positioned to capitalise on industry trends to outsource drug development services, as well as the continued need for alternative sources of funding for drug development by both mid-cap pharmaceutical and biotech companies.
"We look forward to expanding and accelerating our core services business and creating value from our co-development business. We would like to welcome our new investors and look forward to updating them on our progress as we continue to grow the company.”
Oriel Securities led the placing. Ergomed was advised by Deloitte, Covington and Burlington LLP and Hume Brophy Communications.